

1 Introduction

One of the most powerful tools for receptor research and drug discovery is the study of receptor-ligand interactions.

Historically, radioactive ligands have been used to identify a binding event; however, there are numerous limitations involved in the use of radioactivity for high-throughput screening.

The recent development of high-throughput confocal imaging plate readers such as the ImageXpress^{ULTRA}™ from MDS Analytical Technologies and the concurrent development of high affinity fluorescent ligands which selectively bind to G-protein coupled receptors (GPCRs) has provided a novel and non-radioactive alternative for the determination of ligand binding affinities.

In this study we have developed a ligand binding assay which takes advantage of both high affinity fluorescent ligands and imaging technology to determine the ligand-binding characteristics at five functionally and structurally distinct GPCRs (the adenosine A1, the muscarinic M3, the dopamine D1, the histamine H2 receptor and the β_2 -adrenoceptor (β_2 -AR)).

Collectively these data highlight a novel and quantitative approach to the determination of ligand binding affinities.

2 Methods

Cells were grown to confluence in 96-well black view plates (Corning Costar) in DMEM/F12 medium supplemented with 10% fetal calf serum and 2mM glutamine at 37°C, 5% CO₂/humidified air.

- On the day of experimentation all media were removed and the cells stained with 1 μ g/ml Hoechst stain in hepes buffered saline (HBS) for 10 minutes at room temperature.

- Cells were washed once with HBS and resuspended in a final volume of 100 μ l/well HBS.

- Unlabelled competitors were pre-incubated on cells for 30 minutes at room temperature prior to the addition of a receptor selective fluorescent ligand (Table 1; CellAura Technologies Ltd.).

- Fluorescent ligand binding was detected over a 10 minute period on the ImageXpress^{ULTRA}™.

- Fluorescent ligands were excited by a 633nm laser. The Hoechst stain was excited by a 405nm laser.

3 Imaging data

- Fully automated point-scanning confocal imaging system.
- Up to 4 solid state lasers for simultaneous or sequential scanning.
- User selectable self-aligning main beam-splitters.
- Dedicated high-speed laser auto-focus to minimize sample bleaching.
- 4-position automated objective changer.
- Up to 3 user-selectable filter sets.
- Z focus with better than 100nm resolution.
- Software-configurable detection pinhole diameter.




Figure 1: ImageXpress^{ULTRA}™

4 Results

Binding




Figure 2: Selective membrane binding of each fluorescent ligand was detected at a final concentration of 100nM in CHO cells stably expressing the target receptor. Selective membrane binding of the fluorescent ligand was displaced by a 30 minute pre-incubation with an unlabelled competitor (final concentration of 10 μ M).

5 Image Analysis

Membrane bound fluorescence was quantified using the MetaMorph™ analysis software from MDS Analytical Technologies.

The signal to noise ratio was improved by filtering each image through a ranking algorithm. A rank was applied to each pixel with the background representing the lowest rank.

A threshold was then applied to each image to eliminate background fluorescence while identifying membrane bound fluorescence.

The integrated intensity was then calculated within a given area of each image.




Figure 3: MetaMorph™ analysis of membrane bound β_2 -633-AG fluorescence in CHO cells stably expressing the β_2 -AR. By applying a threshold to the ranked imaged (A) only membrane bound fluorescence is identified hence eliminating any background or non-membrane bound fluorescence (B).

6 Saturation Binding Data




Figure 4: Specific binding of β_2 -633-AG (A) and D-633-AN (B) was determined in CHO cells stably expressing the human β_2 -AR or the dopamine D1 receptor respectively. Specific binding was taken as that displaceable by 10 μ M unlabelled ICI 118551 (β_2 -AR) or 10 μ M SCH 23390 (dopamine D1 receptor). Whole cell saturation binding studies on CHO- β_2 cells gave a logK_D value of -6.49 (β_2 -633-AG) while studies on CHO-D1 cells gave a logK_D value of -5.92 (D-633-AN).

7 Competitive Binding




Figure 5: The β_2 -selective antagonist ICI 118551 decreased binding of 100nM β_2 -633-AG to the β_2 -AR in a dose dependent manner (A). Unlabelled ICI 118551 decreased β_2 -633-AG binding to the β_2 -AR by 98.21 \pm 5.61%. A logK_i value for this event was calculated at -9.07 \pm 0.45. The selective D1-antagonist SCH 23390 decreased binding of 100nM D-633-AN to the D1-receptor in a dose dependent manner (B). Unlabelled SCH 23390 decreased D-633-AN binding by 105.66 \pm 3.51% and producing a logK_i value of -8.41 \pm 0.32.

8 Ligand Portfolio

Receptor	CellAura Ligand	Antagonist
Adenosine A1	A-633-AN	XAC
Dopamine D1	D-633-AN	SCH 23390
Histamine H2	H2-633-AN	Ranitidine
Muscarinic M3	M3-633-AN	Pirenzepine
β_2 -Adrenoceptor	β_2 -633-AN	ICI 118551
β_2 -Adrenoceptor	β_2 -633-AG	ICI 118551

Table 1: Description of all receptors reviewed in this study including their corresponding fluorescent ligands and unlabelled competitors. CellAura Technologies offers a wide range of high affinity fluorescent ligands for GPCRs which have comparable pharmacological properties to the parent ligand.

9 Discussion

These data indicate that ligand binding assays based on the compatibility between fluorescent ligand technology and the ImageXpress^{ULTRA}™ provide a novel approach for the characterisation of the receptor-ligand interaction and highlight its future application in drug discovery.